Healthy Skepticism Library item: 3482

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

MLAM letter follow up—Pfizer
1987 Feb; 2

Abstract:

In response to the MLAM letter about piroxicam Pfizer sent a 10 page reply with a folder consisting of mostly unpublished references. However, Pfizer did not address the issue of tolerance in the elderly or provide evidence that piroxicam has a low incidence of side effects compared to other NSAIDs.

Keywords:
*analysis/developing countries/piroxicam/Pfizer/NSAID/ company responses/ nonsteroidal anti-inflammatory drugs/ safety & risk information/ quality of information/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES/REGULATION, CODES, GUIDELINES: FEEDBACK TO COMPANIES